Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.

ABSTRACT:

Unlabelled

Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance.

Introduction

This 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the fina

SUBMITTER: McClung MR 

PROVIDER: S-EPMC3536960 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature